Aristeia Capital’s Celularity CELU Stock Holding History

Aristeia Capital’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,080	Closed	-$1.37M	–	265
2020 Q3	$1.37M	Buy	+13,080	New	+$1.35M	0.06%	158

Other funds holding CELU

BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Aristeia Capital's CELU Position: Q4 2020 in Review

Aristeia Capital sold out of Celularity (CELU) in Q4 2020, closing a stake of 13,080 shares — an estimated $1.37M sold.

Aristeia Capital first reported a position in CELU in Q3 2020 and held it in 1 quarter. The position peaked at $1.37M in Q3 2020. 64 funds tracked by Wall St. Rank hold CELU as of Q4 2020.

Aristeia Capital reported no remaining Celularity position as of Q4 2020 after selling out during the quarter.
Aristeia Capital sold 13,080 Celularity shares in Q4 2020, an estimated $1.37M.
Aristeia Capital first reported a position in Celularity in Q3 2020 and held it in 1 quarter.
Aristeia Capital's Celularity position peaked at $1.37M in Q3 2020.
64 funds tracked by Wall St. Rank held Celularity as of Q4 2020.

Based on Aristeia Capital's 13F filing for Q4 2020, filed 16 Feb 2021.